It was a pleasure to speak with Prof. Laure Gossec (Sorbonne Universite, Paris, France) about the recent real-world data surrounding the long-term persistence of ustekinumab and TNF inhibitors in patients with PsA (NCT02627768).
The abstract entitled ‘Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study’ (ABSTRACT NUMBER: 1339) was presented at the ACR Convergence, 5-9 November 2021.
- What were the aims and design of the PsABio study? (0:10)
- What were the study findings across different treatment groups? (0:39)
- What were the reasons for discontinuing treatment? (1:49)
- On the basis of these findings, what factors should be taken into account when deciding to prescribe ustekinumab or TNF inhibitors in people with PsA? (2:41)
Disclosures: Prof. Laure Gossec has received honoraria from Janssen in relation to this study and is also the international Principal Investigator.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Psoriatic Arthritis
Merav Lidar, ACR 2021: Efficacy and Safety of Risankizumab in Psoriatic Arthritis
Prof. Merav Lidar (Sheba Medical Center, Tel Hashomer, Israel) kindly took the time to discuss the 24-week efficacy and safety results from the KEEPsaKE2 trial (NCT03671148). This phase 3 randomized, double-blind trial investigated the humanized immunoglobulin G1 monoclonal antibody, risankizumab, in adults with psoriatic arthritis (PsA). The abstract entitled ‘Efficacy and Safety of Risankizumab for […]
Ana-Maria Orbai, ACR 2021: Effect of Guselkumab on General Health Outcomes using the PROMIS-29
touchIMMUNOLOGY had the pleasure of discussing with Dr Ana-Maria Orbai (Johns Hopkins University School of Medicine, Baltimore, MD, USA) the Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29) instrument and its use in assessing the effect of guselkumab on general health outcomes in patients with psoriatic arthritis in the DISCOVER-1 trial (NCT03162796). The abstract entitled ‘Guselkumab-Treated Patients […]
Laure Gossec, ACR 2021: Long-term Impact of Bimekizumab on Patient-reported Outcomes in PsA
Prof. Laure Gossec (Sorbonne Universite, Paris, France) kindly took the time to speak with touchIMMUNOLOGY about the long-term impact of the IgG1 inhibitor, bimekizumab, on patient-reported outcomes from the phase 2b BE ACTIVE study (NCT02969525) and its open-label extension, the OLE trial (NCT03347110). The poster entitled ‘Sustained Improvement in Physical Function, Disease Impact and Health-Related […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!